Abstract | OBJECTIVE: MATERIALS AND METHODS: The was conducted in a specialized tuberculosis ward for multidrug-resistant tuberculosis (MDR-TB) on the Chest Service of Bellevue Hospital Center, which is a 768-bed public hospital in New York City. Seven patients with confirmed MDR-TB or XDR-TB who were still culture positive despite appropriate directly observed therapy were treated with a regimen containing linezolid and at least one other active agent. RESULTS: The linezolid-containing regimen led to sustained negative conversion of sputum cultures and radiographic improvement in all patients. Long-term therapy (longest duration of therapy, 28 months) was well tolerated in most patients. Neutropenia developed in three patients, but was reversible, and peripheral neuropathy developed in two patients. CONCLUSIONS:
Linezolid remains a promising possible addition to our therapeutic armamentarium against XDR-TB. Linezolid is associated with side effects that can be adequately managed. Further studies to define the mechanism of action and optimum dose should be performed.
|
Authors | Rany Condos, Nicos Hadgiangelis, Eric Leibert, Germaine Jacquette, Timothy Harkin, William N Rom |
Journal | Chest
(Chest)
Vol. 134
Issue 1
Pg. 187-92
(Jul 2008)
ISSN: 0012-3692 [Print] United States |
PMID | 18628223
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Acetamides
- Anti-Infective Agents
- Oxazolidinones
- Linezolid
|
Topics |
- Acetamides
(adverse effects, therapeutic use)
- Adult
- Anti-Infective Agents
(adverse effects, therapeutic use)
- Child
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Extensively Drug-Resistant Tuberculosis
(drug therapy)
- Female
- Humans
- Linezolid
- Male
- Middle Aged
- Oxazolidinones
(adverse effects, therapeutic use)
- Tuberculosis, Multidrug-Resistant
(diagnosis, drug therapy)
|